Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Dr Rebecca Auer


Contact details

St Barts and the London NHS Trust
Dept Medical Oncology
St Barts Hospital
45 Little Britain
West Smithfield
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A phase II study of GCS-100 in combination with chemo-immunotherapy in relapsed or refractory diffuse large B-cell lymphoma


Study hypothesis

The primary objective of this study is to assess the efficacy of GCS-100 with rituximab, ifosfomide, mesna, carboplatin and etoposide (R-ICE) chemotherapy in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The secondary objective is to determine the safety of GCS-100 in conjunction with cytotoxic chemotherapy.

Ethics approval

The study was approved by the London Research Ethics Committee (REC) of Northwick Park Hospital on the 6th October 2008 (ref: 08/H0718/57)

Study design

Interventional, single-arm, single-centre trial

Primary study design


Secondary study design


Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)


This is a single-arm trial of GCS-100 with R-ICE chemotherapy administered in 21-day cycles (a maximum of four chemotherapy cycles per participant). Each 21-day treatment cycle consists of the following:

Days 1 - 5: GCS-100 160 mg/m^2/day intravenously (IV) over 1 hour.

Dosing with GCS-100 will be followed at least 1 hour later by:
Day 1: rituximab 375 mg/m^2 IV
Days 2: carboplatin dose area under the curve (AUC) = 5 mg/mL x min (maximum 800 mg) IV
Days 2 - 4: ifosfamide 1667 mg/m^2 IV
Days 2 - 4: mesna 1667 mg/m^2 IV or oral
Days 2 - 4: etoposide 100 mg/m^2 IV

Intervention type



Phase II

Drug names

GCS-100, rituximab, ifosfomide, mesna, carboplatin, etoposide

Primary outcome measure

1. Response: overall response rate, defined as the sum of the number of CR rate and PR rate. CR and PR will be defined according to the International Harmonisation Project for Lymphoma criteria.
2. Imaging: CT scans will be obtained at baseline and every two cycles to assess for response. They will be evaluated according to the International Harmonisation Project for Lymphoma.

Total duration of follow-up for the primary and secondary outcome measures: 16 weeks.

Secondary outcome measures

To determine the safety of GCS-100 in conjunction with cytotoxic chemotherapy by collecting adverse event data and monitoring blood parameters, etc. Total duration of follow-up for the primary and secondary outcome measures: 16 weeks.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)

Lack of funding/sponsorship


Participant inclusion criteria

1. Subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent
2. Subject is male or female, aged at least 18 years
3. Subject has histologically confirmed DLBCL, bidimensionally measurable by computerised tomography (CT) scan, with at least one lesion greater than or equal to 1.5 cm in the greatest diameter. CT scan results must be available prior to dosing to establish eligibility.
4. Subject has relapsed or relapsed/refractory disease following at least two cycles of R-ICE chemotherapy as salvage chemotherapy, without partial response (PR) or complete response (CR)
5. Subject has greater than or equal to 4 weeks elapsed between last chemotherapy or immunotherapy exposure
6. Subject has Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1

Participant type


Age group




Target number of participants

14 - 28

Participant exclusion criteria

1. Subject has received high-dose chemotherapy with haematopoietic stem cell support or allogeneic stem cell transplantation (SCT)
3. Subject has rapidly progressive lymphoma or lymphoma threatening organ function
4. Subjects with primary or secondary central nervous system lymphoma
5. Subjects who have had treatment with an experimental (unlicensed) drug within 3 weeks prior to treatment with GCS-100
6. Subject has not recovered from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy
7. Subject has a known history of human immunodeficiency virus-related lymphoma, active hepatitis C, active hepatitis B, or prior history of infection with hepatitis B (HBcAb positive)
8. Subject has a clinically relevant active infection and/or a serious co-morbid medical condition such as recent myocardial infarction (within the last 6 months and no electrocardiographic evidence of acute ischaemia or new conduction system abnormalities), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.
9. Subject had major surgery within 4 weeks prior to study day 1

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

St Barts and the London NHS Trust
United Kingdom

Sponsor information


Prospect Therapeutics, Inc. (USA)

Sponsor details

12 Gill Street
Suite 4700
MA 01801
United States of America

Sponsor type




Funder type


Funder name

Prospect Therapeutics, Inc. (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes